Recombinant; Rabbit anti Human MMP14 Antibody; WB, IHC; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab115644-10μl | 10μl | In stock | $76.90 | |
| Ab115644-50μl | 50μl | In stock | $219.90 | |
| Ab115644-100μl | 100μl | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $339.90 | |
| Ab115644-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,809.90 |
Recombinant; Rabbit anti Human MMP14 Antibody; WB, IHC; Unconjugated
| Product Name | Recombinant MMP14 Antibody - Primary antibody, specific to MMP14, Rabbit IgG |
|---|---|
| Synonyms | Matrix metallopeptidase 14 (membrane inserted) antibody; Matrix metalloproteinase 14antibody; Matrix metalloproteinase-14 antibody; Membrane type 1 matrix metalloproteinaseantibody; Membrane type 1 metalloprotease antibody; Membrane type matrix metallopro |
| Specifications & Purity | ExactAb™, Validated, Recombinant, 0.2 mg/mL |
| Host species | Rabbit |
| Specificity | MMP14 |
| Immunogen | A synthetic peptide derived from human MMP14 (AA 161-174). |
| Positive Control | WB: A431, HUVEC and NIH/3T3 cell lysates. IHC: Human breast cancer tissue. |
| Conjugation | Unconjugated |
| Grade | ExactAb™, Recombinant, Validated |
| Product Description | Rabbit anti Human MMP14 Antibody, Recombinant, could be used for WB, IHC and so on. |
| Isotype | Rabbit IgG |
|---|---|
| SDS-PAGE | 150 kDa |
| Purification Method | Antigen affinity purified |
| Form | Liquid |
| Concentration | 0.2 mg/mL |
| Storage Temp | Store at -20°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at 4°C short term (1-2 weeks). Store at -20°C long term (24 months). Upon delivery aliquot. Avoid freeze/thaw cycle. |
Recombinant MMP14 Antibody (Ab115644) - Western Blot
All lanes: Recombinant MMP14 Antibody (Ab115644) at 1/2000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution
Predicted band size: 66 kDa
Observed band size: 55 kDa
Exposure time: 103.0 s
Recombinant MMP14 Antibody (Ab115644) - Western Blot
All lanes: Recombinant MMP14 Antibody (Ab115644) at 1/2000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution
Predicted band size: 66 kDa
Observed band size: 55 kDa
Exposure time: 5.0 s
Recombinant MMP14 Antibody (Ab115644) - IHC
Immunohistochemistry analysis of paraffin-embedded Human breast cancer using Recombinant MMP14 Antibody (Ab115644). High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Application | Dilution info |
|---|---|
| WB | 1/500-1/2000 |
| IHC | 1/50 - 1/100 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0303006 | Certificate of Analysis | Mar 08, 2024 | Ab115644 |
| ZJ24F0303007 | Certificate of Analysis | Mar 08, 2024 | Ab115644 |
| 1. Cork SM, Kaur B, Devi NS, Cooper L, Saltz JH, Sandberg EM, Kaluz S, Van Meir EG. (2012) A proprotein convertase/MMP-14 proteolytic cascade releases a novel 40 kDa vasculostatin from tumor suppressor BAI1.. Oncogene, 31 (50): (5144-52). [PMID:22330140] |
| 2. De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J et al.. (2011) Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.. Bioorg Med Chem Lett, 21 (11): (3301-6). [PMID:21536437] |
| 3. Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX. (2013) Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.. J Med Chem, 56 (11): (4357-73). [PMID:23631440] |
| 4. Johnson AR, Pavlovsky AG, Ortwine DF, Prior F, Man CF, Bornemeier DA, Banotai CA, Mueller WT, McConnell P, Yan C et al.. (2007) Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.. J Biol Chem, 282 (38): (27781-91). [PMID:17623656] |
| 5. Georgiadis D, Yiotakis A. (2008) Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.. Bioorg Med Chem, 16 (19): (8781-94). [PMID:18790648] |
| 6. Kwan JC, Eksioglu EA, Liu C, Paul VJ, Luesch H. (2009) Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.. J Med Chem, 52 (18): (5732-47). [PMID:19715320] |
| 7. Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E et al.. (2011) Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.. Eur J Med Chem, 46 (7): (2617-29). [PMID:21514700] |
| 8. Mott BT, Ferreira RS, Simeonov A, Jadhav A, Ang KK, Leister W, Shen M, Silveira JT, Doyle PS, Arkin MR et al.. (2010) Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.. J Med Chem, 53 (1): (52-60). [PMID:19908842] |
| 9. Ruminski PG, Massa M, Strohbach J, Hanau CE, Schmidt M, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Shieh HS et al.. (2016) Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.. J Med Chem, 59 (1): (313-27). [PMID:26653735] |
| 10. Guan-Sheng Jiao,Seongjin Kim,Mahtab Moayeri,Devorah Crown,April Thai,Lynne Cregar-Hernandez,Linda McKasson,Banumathi Sankaran,Axel Lehrer,Teri Wong,Lisa Johns,Stephen A Margosiak,Stephen H Leppla,Alan T Johnson. (2012-02-22) Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.. Bioorganic & medicinal chemistry letters, 22 ((6)): (2242-2246). [PMID:22342144] |
| 11. Major Gooyit,Wei Song,Kiran V Mahasenan,Katerina Lichtenwalter,Mark A Suckow,Valerie A Schroeder,William R Wolter,Shahriar Mobashery,Mayland Chang. (2013-09-14) O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.. Journal of medicinal chemistry, 56 ((20)): (8139-8150). [PMID:24028490] |
| 12. Anna M Knapinska,Daniela Dreymuller,Andreas Ludwig,Lyndsay Smith,Vladislav Golubkov,Anjum Sohail,Rafael Fridman,Marc Giulianotti,Travis M LaVoi,Richard A Houghten,Gregg B Fields,Dmitriy Minond. (2015-07-21) SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.. Journal of medicinal chemistry, 58 ((15)): (5808-5824). [PMID:26192023] |
| 13. Xiang JS, Hu Y, Rush TS, Thomason JR, Ipek M, Sum PE, Abrous L, Sabatini JJ, Georgiadis K, Reifenberg E, Majumdar M, Morris EA, Tam S.. (2006) Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors.. Bioorg Med Chem Lett, 16 (2): (311-316). [PMID:16275085] |
| 14. Santos MA, Enyedy EA, Nuti E, Rossello A, Krupenko NI, Krupenko SA.. (2007) Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.. Bioorg Med Chem, 15 (3): (1266-1274). [PMID:17127067] |
| 15. Li JJ, Nahra J, Johnson AR, Bunker A, O'Brien P, Yue WS, Ortwine DF, Man CF, Baragi V, Kilgore K, Dyer RD, Han HK.. (2008) Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.. J Med Chem, 51 (4): (835-841). [PMID:18251495] |
| 16. Watkins GA, Jones EF, Scott Shell M, VanBrocklin HF, Pan MH, Hanrahan SM, Feng JJ, He J, Sounni NE, Dill KA, Contag CH, Coussens LM, Franc BL.. (2009) Development of an optimized activatable MMP-14 targeted SPECT imaging probe.. Bioorg Med Chem, 17 (2): (653-659). [PMID:19109023] |
| 17. Li W, Li J, Wu Y, Wu J, Hotchandani R, Cunningham K, McFadyen I, Bard J, Morgan P, Schlerman F, Xu X, Tam S, Goldman SJ, Williams C, Sypek J, Mansour TS.. (2009) A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408).. J Med Chem, 52 (7): (1799-1802). [PMID:19278250] |
| 18. Monovich LG, Tommasi RA, Fujimoto RA, Blancuzzi V, Clark K, Cornell WD, Doti R, Doughty J, Fang J, Farley D, Fitt J, Ganu V, Goldberg R, Goldstein R, Lavoie S, Kulathila R, Macchia W, Parker DT, Melton R, O'Byrne E, Pastor G, Pellas T, Quadros E, Reel N, Roland DM, Sakane Y, Singh H, Skiles J, Somers J, Toscano K, Wigg A, Zhou S, Zhu L, Shieh WC, Xue S, McQuire LW.. (2009) Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.. J Med Chem, 52 (11): (3523-3538). [PMID:19422229] |
| 19. Hopper DW, Vera MD, How D, Sabatini J, Xiang JS, Ipek M, Thomason J, Hu Y, Feyfant E, Wang Q, Georgiadis KE, Reifenberg E, Sheldon RT, Keohan CC, Majumdar MK, Morris EA, Skotnicki J, Sum PE.. (2009) Synthesis and biological evaluation of ((4-keto)-phenoxy)methyl biphenyl-4-sulfonamides: a class of potent aggrecanase-1 inhibitors.. Bioorg Med Chem Lett, 19 (9): (2487-2491). [PMID:19329309] |
| 20. Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A.. (2009) N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.. J Med Chem, 52 (15): (4757-4773). [PMID:19606871] |
| 21. Li W, Li J, Wu Y, Rancati F, Vallese S, Raveglia L, Wu J, Hotchandani R, Fuller N, Cunningham K, Morgan P, Fish S, Krykbaev R, Xu X, Tam S, Goldman SJ, Abraham W, Williams C, Sypek J, Mansour TS.. (2009) Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.. J Med Chem, 52 (17): (5408-5419). [PMID:19725580] |
| 22. Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A.. (2009) Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.. J Med Chem, 52 (20): (6347-6361). [PMID:19775099] |
| 23. Schnute ME, O'Brien PM, Nahra J, Morris M, Howard Roark W, Hanau CE, Ruminski PG, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Patt WC, Shieh HS, Collins B, Pavlovsky AG, Palmquist KE, Aston KW, Hitchcock J, Rogers MD, McDonald J, Johnson AR, Munie GE, Wittwer AJ, Man CF, Settle SL, Nemirovskiy O, Vickery LE, Agawal A, Dyer RD, Sunyer T.. (2010) Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.. Bioorg Med Chem Lett, 20 (2): (576-580). [PMID:20005097] |
| 24. Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A.. (2010) Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.. J Med Chem, 53 (6): (2622-2635). [PMID:20180536] |
| 25. Testero SA, Lee M, Staran RT, Espahbodi M, Llarrull LI, Toth M, Mobashery S, Chang M.. (2011) Sulfonate-containing thiiranes as selective gelatinase inhibitors.. ACS Med Chem Lett, 2 (2): (177-181). [PMID:24900296] |
| 26. De Savi C, Pape A, Cumming JG, Ting A, Smith PD, Burrows JN, Mills M, Davies C, Lamont S, Milne D, Cook C, Moore P, Sawyer Y, Gerhardt S.. (2011) The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.. Bioorg Med Chem Lett, 21 (5): (1376-1381). [PMID:21300546] |
| 27. Shiozaki M, Maeda K, Miura T, Kotoku M, Yamasaki T, Matsuda I, Aoki K, Yasue K, Imai H, Ubukata M, Suma A, Yokota M, Hotta T, Tanaka M, Hase Y, Haas J, Fryer AM, Laird ER, Littmann NM, Andrews SW, Josey JA, Mimura T, Shinozaki Y, Yoshiuchi H, Inaba T.. (2011) Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.. J Med Chem, 54 (8): (2839-2863). [PMID:21417219] |
| 28. Gooyit M, Lee M, Schroeder VA, Ikejiri M, Suckow MA, Mobashery S, Chang M.. (2011) Selective water-soluble gelatinase inhibitor prodrugs.. J Med Chem, 54 (19): (6676-6690). [PMID:21866961] |
| 29. Neelarapu R, Holzle DL, Velaparthi S, Bai H, Brunsteiner M, Blond SY, Petukhov PA.. (2011) Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.. J Med Chem, 54 (13): (4350-4364). [PMID:21548582] |
| 30. La Pietra V, Marinelli L, Cosconati S, Di Leva FS, Nuti E, Santamaria S, Pugliesi I, Morelli M, Casalini F, Rossello A, La Motta C, Taliani S, Visse R, Nagase H, da Settimo F, Novellino E.. (2012) Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.. Eur J Med Chem, 47 (143-152). [PMID:22088955] |
| 31. Roth J, Minond D, Darout E, Liu Q, Lauer J, Hodder P, Fields GB, Roush WR.. (2011) Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.. Bioorg Med Chem Lett, 21 (23): (7180-7184). [PMID:22018790] |
| 32. De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S.. (2012) Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.. Bioorg Med Chem Lett, 22 (1): (271-277). [PMID:22153941] |
| 33. Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I.. (2012) In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.. Bioorg Med Chem, 20 (7): (2323-2337). [PMID:22386984] |
| 34. Gege C, Bao B, Bluhm H, Boer J, Gallagher BM, Korniski B, Powers TS, Steeneck C, Taveras AG, Baragi VM.. (2012) Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.. J Med Chem, 55 (2): (709-716). [PMID:22175799] |
| 35. Lee M, Ikejiri M, Klimpel D, Toth M, Espahbodi M, Hesek D, Forbes C, Kumarasiri M, Noll BC, Chang M, Mobashery S.. (2012) Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.. ACS Med Chem Lett, 3 (6): (490-495). [PMID:22737278] |
| 36. Salvador LA, Taori K, Biggs JS, Jakoncic J, Ostrov DA, Paul VJ, Luesch H.. (2013) Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells.. J Med Chem, 56 (3): (1276-1290). [PMID:23350733] |
| 37. Nuti E, Santamaria S, Casalini F, Yamamoto K, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Marini AM, Salerno S, Taliani S, Da Settimo F, Nagase H, Rossello A.. (2013) Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.. Eur J Med Chem, 62 (379-394). [PMID:23376997] |
| 38. Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A.. (2013) Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.. J Med Chem, 56 (20): (8089-8103). [PMID:24044434] |
| 39. Sodji QH, Patil V, Kornacki JR, Mrksich M, Oyelere AK.. (2013) Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.. J Med Chem, 56 (24): (9969-9981). [PMID:24304348] |
| 40. Nara H, Sato K, Naito T, Mototani H, Oki H, Yamamoto Y, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M.. (2014) Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.. J Med Chem, 57 (21): (8886-8902). [PMID:25264600] |
| 41. Durham TB, Klimkowski VJ, Rito CJ, Marimuthu J, Toth JL, Liu C, Durbin JD, Stout SL, Adams L, Swearingen C, Lin C, Chambers MG, Thirunavukkarasu K, Wiley MR.. (2014) Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.. J Med Chem, 57 (24): (10476-10485). [PMID:25415648] |
| 42. Camodeca C, Nuti E, Tepshi L, Boero S, Tuccinardi T, Stura EA, Poggi A, Zocchi MR, Rossello A.. (2016) Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.. Eur J Med Chem, 111 (193-201). [PMID:26871660] |
| 43. Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.. (2016) Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.. Bioorg Med Chem, 24 (18): (4291-4309). [PMID:27452283] |
| 44. Nara H, Sato K, Kaieda A, Oki H, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M.. (2016) Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.. Bioorg Med Chem, 24 (23): (6149-6165). [PMID:27825552] |
| 45. Durham TB, Marimuthu J, Toth JL, Liu C, Adams L, Mudra DR, Swearingen C, Lin C, Chambers MG, Thirunavukkarasu K, Wiley MR.. (2017) A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human Dose.. J Med Chem, 60 (13): (5933-5939). [PMID:28613895] |
| 46. Choi JY, Fuerst R, Knapinska AM, Taylor AB, Smith L, Cao X, Hart PJ, Fields GB, Roush WR.. (2017) Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.. J Med Chem, 60 (13): (5816-5825). [PMID:28653849] |
| 47. Senn N, Ott M, Lanz J, Riedl R.. (2017) Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.. J Med Chem, 60 (23): (9585-9598). [PMID:28953404] |
| 48. Baggio C, Cerofolini L, Fragai M, Luchinat C, Pellecchia M.. (2018) HTS by NMR for the Identification of Potent and Selective Inhibitors of Metalloenzymes.. ACS Med Chem Lett, 9 (2): (137-142). [PMID:29456802] |
| 49. Fuerst R, Yong Choi J, Knapinska AM, Smith L, Cameron MD, Ruiz C, Fields GB, Roush WR.. (2018) Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.. Bioorg Med Chem, 26 (18): (4984-4995). [PMID:30249495] |
| 50. Boiteau JG, Ouvry G, Arlabosse JM, Astri S, Beillard A, Bhurruth-Alcor Y, Bonnary L, Bouix-Peter C, Bouquet K, Bourotte M, Cardinaud I, Comino C, Deprez B, Duvert D, Féret A, Hacini-Rachinel F, Harris CS, Luzy AP, Mathieu A, Millois C, Orsini N, Pascau J, Pinto A, Piwnica D, Polge G, Reitz A, Reversé K, Rodeville N, Rossio P, Spiesse D, Tabet S, Taquet N, Tomas L, Vial E, Hennequin LF.. (2018) Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis.. Bioorg Med Chem, 26 (4): (945-956). [PMID:28818461] |
| 51. Stallivieri A, Colombeau L, Devy J, Etique N, Chaintreuil C, Myrzakhmetov B, Achard M, Baros F, Arnoux P, Vanderesse R, Frochot C.. (2018) New photodynamic molecular beacons (PMB) as potential cancer-targeted agents in PDT.. Bioorg Med Chem, 26 (3): (688-702). [PMID:29338907] |
| 52. Baggio C,Velazquez JV,Fragai M,Nordgren TM,Pellecchia M. (2020) Therapeutic Targeting of MMP-12 for the Treatment of Chronic Obstructive Pulmonary Disease.. J Med Chem, 63 (21): (12911-12920). [PMID:33107733] |
| 53. Will, H H and Hinzmann, B B.. (1995) cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment.. European journal of biochemistry, (1): [PMID:7649159] |
| 54. Okada, A A and 6 more authors.. (1995) Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas.. Proceedings of the National Academy of Sciences of the United States of America, (28): [PMID:7708715] |
| 55. Takino, T T, Sato, H H, Yamamoto, E E and Seiki, M M.. (1995) Cloning of a human gene potentially encoding a novel matrix metalloproteinase having a C-terminal transmembrane domain.. Gene, (3): [PMID:7721107] |
| 56. Sato, H H and 6 more authors.. (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells.. Nature, (7): [PMID:8015608] |
| 57. Lohi, J J, Lehti, K K, Westermarck, J J, Kähäri, V M VM and Keski-Oja, J J.. (1996) Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate.. European journal of biochemistry, (15): [PMID:8706726] |
| 58. Sato, H H, Kinoshita, T T, Takino, T T, Nakayama, K K and Seiki, M M.. (1996) Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2.. FEBS letters, (9): [PMID:8804434] |
| 59. Fernandez-Catalan, C C and 7 more authors.. (1998) Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor.. The EMBO journal, (1): [PMID:9724659] |
| 60. Heilig, Roland R and 98 more authors.. (2003) The DNA sequence and analysis of human chromosome 14.. Nature, (6): [PMID:12508121] |
| 61. Noda, Kousuke K and 6 more authors.. (2003) Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy.. Investigative ophthalmology & visual science, [PMID:12714657] |
| 62. Zhang, Yuhua Y and 19 more authors.. (2004) Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.. The Journal of pharmacology and experimental therapeutics, [PMID:14718605] |
| 63. Chi, An A and 16 more authors.. (2006) Proteomic and bioinformatic characterization of the biogenesis and function of melanosomes.. Journal of proteome research, [PMID:17081065] |
| 64. Bonnomet, A A and 9 more authors.. (2008) The E-cadherin-repressed hNanos1 gene induces tumor cell invasion by upregulating MT1-MMP expression.. Oncogene, (12): [PMID:18223680] |
| 65. Radichev, Ilian A IA and 6 more authors.. (2010) Biochemical characterization of the cellular glycosylphosphatidylinositol-linked membrane type-6 matrix metalloproteinase.. The Journal of biological chemistry, (21): [PMID:20308072] |
| 66. Golubkov, Vladislav S VS and 9 more authors.. (2010) The Wnt/planar cell polarity protein-tyrosine kinase-7 (PTK7) is a highly efficient proteolytic target of membrane type-1 matrix metalloproteinase: implications in cancer and embryogenesis.. The Journal of biological chemistry, (12): [PMID:20837484] |
| 67. Jin, Guoxiang G and 9 more authors.. (2011) MT1-MMP cleaves Dll1 to negatively regulate Notch signalling to maintain normal B-cell development.. The EMBO journal, (1): [PMID:21572390] |
| 68. Gu, Gongping G, Zhao, Dejian D, Yin, Ziming Z and Liu, Ping P.. (2012) BST-2 binding with cellular MT1-MMP blocks cell growth and migration via decreasing MMP2 activity.. Journal of cellular biochemistry, [PMID:22065321] |
| 69. Evans, Brad R BR and 7 more authors.. (2012) Mutation of membrane type-1 metalloproteinase, MT1-MMP, causes the multicentric osteolysis and arthritis disease Winchester syndrome.. American journal of human genetics, (7): [PMID:22922033] |
| 70. Bordoli, Mattia R MR and 14 more authors.. (2014) A secreted tyrosine kinase acts in the extracellular environment.. Cell, (28): [PMID:25171405] |
